ClinicalTrials.gg
CompletedNCT00888238Updated Jun 26, 2018Results posted

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

A Phase 1 interventional study of sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
178th of 197
12 · median 102
Started
2009
with 11 others
Phase 1
23 of 198
none open now
Registered
69th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 178th largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2009, is one of 23 in phase 1, and was the 69th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an Asian Indian male between 18 to 45 years of age
  • Subject is in good health
  • Subject is a nonsmoker or has not used nicotine-containing products for six months
  • Subject is willing to avoid strenuous activity

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of stroke, seizures, or major neurological disorders
  • Subject has irritable bowel disease or recurrent nausea, vomiting, diarrhea, or abdominal pain
  • Subject has a history of high blood pressure requiring treatment
  • Subject has history of cancer
  • Subject has a history of diabetes
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sitagliptin/Sitagliptin/Placebo

    Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods

    Drug: sitagliptin · Drug: Comparator: Placebo

  • Experimental
    Sitagliptin/Placebo/Sitaglipitin

    Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods

    Drug: sitagliptin · Drug: Comparator: Placebo

  • Experimental
    Placebo/Sitagliptin/Sitagliptin

    Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods

    Drug: sitagliptin · Drug: Comparator: Placebo

Interventions

  • Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.

    Also known as: sitagliptin phosphate, MK0431

  • DrugComparator: Placebo

    Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.

06

What researchers measure

Primary outcomes

  1. Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose

    ISR was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters.

    Time frame: 190 minutes to 340 minutes

Secondary outcomes

  1. Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose

    Glucose Infusion Rate required to maintain the target glucose level of 160 milligrams / deciliter (mg/dL) ; GIR was normalized to subject's body weight (kg).

    Time frame: 190 minutes to 340 minutes

07

Results

Posted Aug 3, 2010

Participant flow

Subjects were recruited at Veeda Clinical Research Pvt. Ltd. in May 2009. First Patient Screened: 20-May-2009. Last Patient, Last Visit: 21-Jul-2009. 1 site

First Period of Treatment Intervention
Participant flow — First Period of Treatment Intervention
MilestoneSitagliptin / Sitagliptin / PlaceboSitagliptin / Placebo / SitagliptinPlacebo / Sitagliptin / Sitagliptin
Started444
Completed444
Not completed000
Washout Period After Period 1
Participant flow — Washout Period After Period 1
MilestoneSitagliptin / Sitagliptin / PlaceboSitagliptin / Placebo / SitagliptinPlacebo / Sitagliptin / Sitagliptin
Started444
Completed444
Not completed000
Second Period of Treatment Intervention
Participant flow — Second Period of Treatment Intervention
MilestoneSitagliptin / Sitagliptin / PlaceboSitagliptin / Placebo / SitagliptinPlacebo / Sitagliptin / Sitagliptin
Started444
Completed444
Not completed000
Washout Period After Period 2
Participant flow — Washout Period After Period 2
MilestoneSitagliptin / Sitagliptin / PlaceboSitagliptin / Placebo / SitagliptinPlacebo / Sitagliptin / Sitagliptin
Started444
Completed443
Not completed001
Withdrew: Adverse event001
Third Period of Treatment Intervention
Participant flow — Third Period of Treatment Intervention
MilestoneSitagliptin / Sitagliptin / PlaceboSitagliptin / Placebo / SitagliptinPlacebo / Sitagliptin / Sitagliptin
Started443
Completed443
Not completed000

Outcome measures

PrimaryInsulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose

ISR was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters.

Time frame:
190 minutes to 340 minutes
Reported as:
Least squares mean · ng/min
Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose
ng/minSitagliptin 100 mgPlacebo
Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose9.73 ± 2.728.03 ± 2.58
Statistical analysis
  • Sitagliptin 100 mg vs Placebo · ANOVA · p = <0.001 · Least squares mean: 1.70 · 90% CI 1.47 to 1.93
SecondaryGlucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose

Glucose Infusion Rate required to maintain the target glucose level of 160 milligrams / deciliter (mg/dL) ; GIR was normalized to subject's body weight (kg).

Time frame:
190 minutes to 340 minutes
Reported as:
Least squares mean · mg / kg / min
Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose
mg / kg / minSitagliptin 100 mgPlacebo
Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose15.0 ± 2.613.7 ± 2.3
Statistical analysis
  • Sitagliptin 100 mg vs Placebo · ANOVA · p = <0.001 · Least squares mean: 1.30 · 90% CI 1.08 to 1.52

Adverse events

Collected over Adverse experiences were collected from the time the consent was signed through the 14 day follow up period, after all treatment periods were completed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg—0/12 (0%)1/12 (8.3%)
Placebo—0/12 (0%)0/12 (0%)
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgPlacebo
BlisterSkin and subcutaneous tissue disorders1/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Patients
Mean26.8 ± 6.4
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female0
Male12
Body Mass Index
Body Mass Index(kg/m2)All Patients
Mean20.5 ± 1.3
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shankar SS, Shankar RR, Mixson LA, Miller DL, Steinberg HO, Beals CR, Kelley DE. Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challenge. Am J Physiol Endocrinol Metab. 2018 Apr 1;314(4):E406-E412. doi: 10.1152/ajpendo.00238.2017. Epub 2017 Nov 14. PubMed 29138226 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2009 to primary completion in Jun 2009, 0 months.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2009
First posted
Apr 27, 2009
StartActual
May 12, 2009
Primary completionActual
Jun 10, 2009
CompletionActual
Jul 21, 2009
Results first posted
Aug 3, 2010
Last update
Jun 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00888238
Responsible party
Sponsor
First posted
Apr 27, 2009
Start date
May 12, 2009
Primary completion
Jun 10, 2009
Completion
Jul 21, 2009
Results posted
Aug 3, 2010
Last update
Jun 26, 2018

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion